Now showing items 1-3 of 3

  • Burger, Emily; de Kok, Inge; Groene, Emily; Killen, Jame; Canfell, Karen; Kulasingam, Shalini; Kuntz, Karen; Matthijsse, Suzette; Regan, Catherine; Simms, Kate; Sy, Stephen; Alarid-Escudero, Fernando; Vaidyanathan, V; van Ballegooijen, Marjolein; Kim, Jane J (Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2019)
    The natural history of human papillomavirus (HPV)-induced cervical cancer (CC) is not directly observable, yet the age of HPV acquisition and duration of preclinical disease (dwell time) influences the effectiveness of ...
  • Kim, Jane J; Simms, Kate T; Killen, James; Smith, Megan A; Burger, Emily; Sy, Stephen; Regan, Catherine; Canfell, Karen (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)
    Background A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 ...
  • Burger, Emily; Jansen, Erik EL; Killen, James; de Kok, Inge; Smith, Megan A; Sy, Stephen; Dunnewind, Niels; Campos, Nicole G.; Haas, Jennifer S; Kobrin, Sarah; Kamineni, Aruna; Canfell, Karen; Kim, Jane J (Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2021)
    Objectives To quantify the secondary impacts of the COVID-19 pandemic disruptions to cervical cancer screening in the United States, stratified by step in the screening process and primary test modality, on cervical ...